BofA/Merrill Lynch Downgrades Dr. Reddy's Laboratories (RDY) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Morgan Stanley Downgrades Dr. Reddy's Laboratories (RDY) to Equalweight
May 14, 2014 7:32 AM EDTMorgan Stanley downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Dr. Reddy's Laboratories click here. For more ratings news on Dr. Reddy's Laboratories click here.
Shares of Dr. Reddy's Laboratories closed at $43.82 yesterday.
... MoreDr. Reddys Labs (RDY) Reports Q4 EPS of $0.47
May 13, 2014 7:03 AM EDTDr. Reddys Labs (NYSE: RDY) reported Q4 EPS of $0.47, versus $0.56 reported last year. Revenue for the quarter came in at $580 million, versus $557 million reported last year.
For earnings history and earnings-related data on Dr. Reddys Labs (RDY) click here.
... More